TY - JOUR
T1 - Detection of Dementia Progression from Functional Activities Data using Machine Learning Techniques
AU - Thabtah, Fadi
AU - Ong, Swan
AU - Peebles, David
N1 - Funding Information:
Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Publisher Copyright:
© 2022-IOS Press. All rights reserved.
PY - 2022/9/29
Y1 - 2022/9/29
N2 - Early screening for Alzheimer’s disease (AD) is crucial for disease management, intervention, and healthcare resource accessibility. Medical assessments of AD diagnosis include the utilisation of biological markers (biomarkers), positron emission tomography (PET) scans, magnetic resonance imaging (MRI) images, and cerebrospinal fluid (CSF). These methods are resource intensive as well as physically invasive, whereas neuropsychological tests are fast, cost effective, and simple to administer for providing early AD diagnosis. However, neuropsychological assessments contain elements related to executive functions, memory, orientation, learning, judgment, and perceptual motor function (among others) that overlap, making it difficult to identify the key elements that trigger the progression of dementia or mild cognitive impairment (MCI). This research investigates the elements of the Functional Activities Questionnaire (FAQ) an early screening method using a data driven approach based on feature selection and classification. The aim is to determine the key items in the FAQ that may trigger AD advancement. To achieve the aim, real data observations of the Alzheimer's Disease Neuroimaging Initiative (ADNI) project have been processed using the proposed data driven approach. The results derived by the machine learning techniques in the proposed approach on data subsets of the FAQ items with demographics show models with accuracy, sensitivity, and specificity all exceeding 90%. In addition, FAQ elements including Administration and Shopping related activities showed correlations with the progression class; these elements cover four out of the six Diagnostic and Statistical Manual’s (DSM-5’s) neurocognitive domains.
AB - Early screening for Alzheimer’s disease (AD) is crucial for disease management, intervention, and healthcare resource accessibility. Medical assessments of AD diagnosis include the utilisation of biological markers (biomarkers), positron emission tomography (PET) scans, magnetic resonance imaging (MRI) images, and cerebrospinal fluid (CSF). These methods are resource intensive as well as physically invasive, whereas neuropsychological tests are fast, cost effective, and simple to administer for providing early AD diagnosis. However, neuropsychological assessments contain elements related to executive functions, memory, orientation, learning, judgment, and perceptual motor function (among others) that overlap, making it difficult to identify the key elements that trigger the progression of dementia or mild cognitive impairment (MCI). This research investigates the elements of the Functional Activities Questionnaire (FAQ) an early screening method using a data driven approach based on feature selection and classification. The aim is to determine the key items in the FAQ that may trigger AD advancement. To achieve the aim, real data observations of the Alzheimer's Disease Neuroimaging Initiative (ADNI) project have been processed using the proposed data driven approach. The results derived by the machine learning techniques in the proposed approach on data subsets of the FAQ items with demographics show models with accuracy, sensitivity, and specificity all exceeding 90%. In addition, FAQ elements including Administration and Shopping related activities showed correlations with the progression class; these elements cover four out of the six Diagnostic and Statistical Manual’s (DSM-5’s) neurocognitive domains.
KW - Alzheimer disease
KW - Classification
KW - clinical informatics
KW - Data analysis
KW - FAQ
KW - ADNI
KW - Machine learing
UR - http://www.scopus.com/inward/record.url?scp=85140620409&partnerID=8YFLogxK
U2 - 10.3233/IDT-220054
DO - 10.3233/IDT-220054
M3 - Article
VL - 16
SP - 615
EP - 630
JO - Intelligent Decision Technologies
JF - Intelligent Decision Technologies
SN - 1872-4981
IS - 3
ER -